Abstract
Lithium, an old and invaluable psychiatric therapy, is still the best treatment option in several clinical circumstances, including acute mania, bipolar and unipolar recurrent mood disorders, suicidal ideation and behavior, recurrent or chronic unipolar depression that has not responded to other treatments, aggressive or impulsive behavior and alcoholism, especially when an affective component is manifest. However, lithium has a narrow therapeutic index and is associated with many serious acute and long-term side effects. Furthermore, monitoring requirements, i.e., frequent blood draws and frequent visits, discourage lithium use. Therefore, the drug is underused. Full awareness of lithium side effects and competence to minimize them is the only contrast to this ominous trend. Renal side effects are frequent in the course of lithium treatment. Although not serious in the large majority of cases, they may seldom become severe and result in chronic renal failure and end stage renal disease. The aim of the paper is reviewing the renal safety profile of lithium and the suggested strategies in the management of the lithium associated renal side effects.
Keywords: Bipolar disorder, lithium, side effects, suicide, treatment, unipolar recurrent mood disorders, NEPHROGENIC DIABETES INSIPIDUS, ACUTE LITHIUM INTOXICATION
Current Drug Safety
Title: Lithium and Kidney, 60 Years Later
Volume: 6 Issue: 5
Author(s): Michele Raja
Affiliation:
Keywords: Bipolar disorder, lithium, side effects, suicide, treatment, unipolar recurrent mood disorders, NEPHROGENIC DIABETES INSIPIDUS, ACUTE LITHIUM INTOXICATION
Abstract: Lithium, an old and invaluable psychiatric therapy, is still the best treatment option in several clinical circumstances, including acute mania, bipolar and unipolar recurrent mood disorders, suicidal ideation and behavior, recurrent or chronic unipolar depression that has not responded to other treatments, aggressive or impulsive behavior and alcoholism, especially when an affective component is manifest. However, lithium has a narrow therapeutic index and is associated with many serious acute and long-term side effects. Furthermore, monitoring requirements, i.e., frequent blood draws and frequent visits, discourage lithium use. Therefore, the drug is underused. Full awareness of lithium side effects and competence to minimize them is the only contrast to this ominous trend. Renal side effects are frequent in the course of lithium treatment. Although not serious in the large majority of cases, they may seldom become severe and result in chronic renal failure and end stage renal disease. The aim of the paper is reviewing the renal safety profile of lithium and the suggested strategies in the management of the lithium associated renal side effects.
Export Options
About this article
Cite this article as:
Raja Michele, Lithium and Kidney, 60 Years Later, Current Drug Safety 2011; 6 (5) . https://dx.doi.org/10.2174/157488611798918737
DOI https://dx.doi.org/10.2174/157488611798918737 |
Print ISSN 1574-8863 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3911 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antidote Control of Aptamer Therapeutics: The Road to a Safer Class of Drug Agents
Current Pharmaceutical Biotechnology Impact of Metformin on Male Reproduction
Current Pharmaceutical Design Cross-Talk Between Mesenchymal Stem/Stromal Cells and Dendritic Cells
Current Stem Cell Research & Therapy Significance of Pharmacogenetics and Pharmacogenomics Research in Current Medical Practice
Current Drug Metabolism Polyphenols can Potentially Prevent Atherosclerosis and Cardiovascular Disease by Modulating Macrophage Cholesterol Metabolism
Current Molecular Pharmacology A Randomized, Double Blind, Controlled, Dose Dependent Clinical Trial to Evaluate the Efficacy of a Proanthocyanidin Standardized Whole Cranberry (Vaccinium macrocarpon) Powder on Infections of the Urinary Tract
Current Bioactive Compounds May Oxygen-Ozone Therapy Improves Cardiovascular Disorders?
Cardiovascular & Hematological Disorders-Drug Targets How to Advise Aspirin Use in Patients Who Need NSAIDs
Current Pharmaceutical Design A Critical and Comprehensive Insight on Heme Oxygenase and Related Products Including Carbon Monoxide, Bilirubin, Biliverdin and Ferritin in Type-1 and Type-2 Diabetes
Current Pharmaceutical Design Novel and Emerging Therapies in Cardiology and Haematology
Current Drug Targets - Cardiovascular & Hematological Disorders Micro RNA: An Epigenetic Regulator of Type 2 Diabetes
MicroRNA The Common Mycobacterial Antigens and their Importance in the Treatment of Disease
Current Pharmaceutical Design Role of Asymmetric Dimethylarginine (ADMA) in Diabetic Vascular Complications
Current Pharmaceutical Design Ca2+ Signalling in Damaged Endothelium: Do Connexin Hemichannels Aid in Filling the Gap?
Current Drug Therapy Diagnosis and Management of Endocrine Hypertension in Children and Adolescents
Current Pharmaceutical Design New Treatments for COPD in the Elderly
Current Pharmaceutical Design Macrocyclic Lactones in the Treatment and Control of Parasitism in Small Companion Animals
Current Pharmaceutical Biotechnology The Polyamine Pathway as a Potential Target for Vascular Diseases: Focus on Restenosis
Current Vascular Pharmacology Progress in the Rational Design for Polypharmacology Drug
Current Pharmaceutical Design The Role of Glycoprotein IIb/IIIa Inhibitors- A Promise Not Kept?
Current Cardiology Reviews